Improving smoking cessation treatments for HIV-positive smokers
Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV
This study is looking at new ways to help people with HIV/AIDS quit smoking by personalizing their treatment based on their genetics and providing extra support, so they can stick to their quit plans and have a better chance of success.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10909972 on NIH RePORTER |
What this research studies
This research investigates new methods to enhance smoking cessation treatments specifically for individuals living with HIV/AIDS. It focuses on personalizing medication choices based on genetic factors that affect nicotine metabolism and improving adherence to treatment plans. By utilizing a tailored approach, the study aims to increase the effectiveness of existing smoking cessation methods, such as nicotine patches and varenicline, for this population. The research also incorporates behavioral interventions to support patients in maintaining their cessation efforts.
Who could benefit from this research
Good fit: Ideal candidates for this research are smokers who are living with HIV/AIDS and seeking assistance to quit smoking.
Not a fit: Patients who do not smoke or are not living with HIV/AIDS may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve smoking cessation rates among HIV-positive individuals, leading to better health outcomes and increased life expectancy.
How similar studies have performed: Previous research has shown that personalized medication approaches and adherence interventions can improve cessation outcomes in other populations, suggesting potential success for this novel approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Schnoll, Robert Adam — University of Pennsylvania
- Study coordinator: Schnoll, Robert Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.